Kim, Damon http://orcid.org/0000-0003-3145-7559
Elgeti, Thomas
Penzkofer, Tobias
Steffen, Ingo G.
Jensen, Laura J.
Schwartz, Stefan
Hamm, Bernd
Nagel, Sebastian N.
Funding for this research was provided by:
Charité
Article History
Received: 27 March 2020
Revised: 8 June 2020
Accepted: 3 August 2020
First Online: 21 August 2020
Compliance with ethical standards
:
: The scientific guarantor of this publication is Sebastian Nagel, MD, Charité - Universitätsmedizin Berlin.
: Bernd Hamm is Grant Recipient for the Department of Radiology, Charité, and has further received funding from Abbott, AbbVie, Ablative Solutions, Accovion, Achaogen lnc., Actelion Pharmaceuticals, ADIR, Aesculap, AGO, AIF Arbeitsgemeinschaft industrieller Forschungsvereinigungen, AIO Arbeitsgemeinschaft lnternistische Onkologie, Alexion Pharmaceuticals, Amgen, AO Foundation, Arena Pharmaceuticals, art photonics GmbH Berlin, ASR Advanced sleep research, Astellas, AstraZeneca, BARD, Bayer Healthcare, Bayer Schering Pharma, Bayer Vital, BBraun, Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT), Berliner Krebsgesellschaft, Biotronik, Bioven, BMBF Bundesministerium für Bildung und Forschung, Boehring Ingelheimer, Boston Biomedical Inc., BRACCO Group, Brainsgate, Bristol-Myers Squibb, Cascadian Therapeutics, lnc., Celgene, CELLACT Pharma, Celldex Therapeutics, CeIoNova BioSciences, Charité research organisation GmbH, Chiltern, CCovance, CUBIST, Curis, Daiichi, DC Devices, lnc. USA, Delcath Systems, Dermira lnc., Deutsche Krebshilfe, Deutsche Rheuma Liga, DFG, DSM Nutritional Products AG, Dt. Stiftung für Herzforschung, Dynavax, Eisai Ltd.‚ European Knowledge Centre, Mosquito Way, Hatfield, Eli Lilly and Company Ltd., EORTC, Epizyme, Inc., Essex Pharma, EU Programmes, Euroscreen S.A., Fibrex Medical Inc., Focused Ultrasound Surgery Foundation, Fraunhofer Gesellschaft, Galena Biopharma, Galmed Research and Development Ltd., Ganymed, GE, Genentech. Inc., GETNE (Grupo Español de Tumores Neuroendocrinos), Gilead Sciences, Inc., Glaxo Smith Kline, Glycotope GmbH, Berlin, Goethe Uni Frankfurt, Guerbet, Guidant Europe NV, Halozyme, Holaira Inc., ICON (CRO), Immunomedics Inc., Immunocore, Incyte, INC Research, Innate Pharma, InSightec Ltd., Inspiremd, inVentiv Health Clinical UK Ltd., Inventivhealth, IOMEDICO, IONIS, IPSEN Pharma, ISA Therapeutics, lsis Pharmaceuticals Inc., ITM Solution GmbH, Jansen, Kantar Health GmbH (CRO), Karyopharm Therapeutics, Inc., Kendle/MorphoSys AG, Kite Pharma, La Roche, Land Berlin, Lilly GmbH, Lion Biotechnology, Lombard Medical, Loxo Oncology, lnc, LSK BioPartners; USA, Lundbeck GmbH, LUX Biosciences, LYSARC, MacroGenics, MagForce, Medlmmune lnc., Medlmmune Limited, Medpace, Medpace Germany GmbH (CRO), MedPass (CRO), Medronic, Merck, Merrimack Pharmaceuticals lnc, MeVis Medical Solutions AG, Millennium Pharmaceuticals Inc., Mologen, MSD Sharp, NeoVacs SA, Nexus Oncology, Novartis, novocure, Nuvisan, Ockham oncology, Orion Corporation Orion Pharma, Parexel CRO Service, Perceptive, Pfizer GmbH, Pharma Mar, Pharmaceutical Research Associates GmbH (PRA), Pharmacyclics Inc., Philipps, PIQUR Therapeutics Ltd., Pluristem, Portola Pharmaceuticals, PPD (CRO), PRAint, Premier-research, Provectus Biopharmaceuticals, Inc., psi-cro, Pulmonx International Sàrl, Quintiles Gmbh, Respicardia, Roche, Samsung, Sanofi, sanofis-aventis S.A, Schumacher GmbH, Seattle Genetics, Servier (CRO), SGS Life Science Services (CRO), Siemens, Silena Therapeutics, Spectranetics GmbH, Spectrum Pharmaceuticals, St. Jude Medical, Stiftung Wolfgang Schulze, Symphogen, Taiho Pharmaceutical Co., Taqu Therapeutics Ltd., Terumo Medical Corporation, Tesaro, TETEC AG, TEVA, Theorem, Theradex, Threshold Pharmaceuticals Inc., TNS Healthcare GmbH, Toshiba, UCB Pharma, Uni München, VDI/VDE, Winicker Norimed, Wyeth Pharma, Xcovery Holding Company, Zukunftsfond Berlin (TSB).Stephan Schwartz reports personal fees and non-financial support from Basilea Pharmaceutica, personal fees and non-financial support from Gilead, personal fees and non-financial support from MSD Sharp & Dohme, personal fees and non-financial support from Pfizer, during the conduct of the study; personal fees and non-financial support from AMGEN, personal fees and non-financial support from BTG International Inc., other from GlaxoSmithKline, personal fees and non-financial support from Jazz Pharmaceuticals, outside the submitted work.Tobias Penzkofer receives grant support from the Berlin Institute of Health within the Clinician Scientist Programme and the Platform programme. TP declares no additional conflict of interest with respect to the relation to the work described. Outside of the current work, there are institutional relationships with the following entities (no personal payments to TP): research support from Siemens Healthcare and Philips Healthcare, clinical trials with AGO, Aprea AB, Astellas Pharma Global Inc., AstraZeneca, Celgene, Genmab A/S, Incyte Coporation, Lion Biotechnologies, Inc., Millennium Pharmaceuticals, Inc., Morphotec Inc., MSD, Tesaro Inc., and Roche.The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: One of the authors (I.S.) has significant statistical expertise.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: This is a subset of patients from a larger prospective study focusing on the use of signal intensity quotients for the differentiation of pulmonary lesions. The results are accepted for publication in another journal and are currently in press. For the texture analysis, the MRI scans were re-evaluated retrospectively.
: • prospective• observational• performed at one institution